According to Li et al., H3K18 lactylation promotes cisplatin resistance in bladder cancer by driving the expression of the transcription factors YBX1 and YY1, and inhibiting H3K18 lactylation can restore cisplatin sensitivity [57]. This evidence concerns the gene YY1 and urinary bladder cancer.